标题
A New Approach to the Management of COVID-19. Antagonists of IL-6: Siltuximab
作者
关键词
-
出版物
ADVANCES IN THERAPY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-01-24
DOI
10.1007/s12325-022-02042-3
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
- (2021) Robert L. Gottlieb et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- COVID antibody treatments show promise for preventing severe disease
- (2021) Heidi Ledford NATURE
- A neutrophil activation signature predicts critical illness and mortality in COVID-19
- (2021) Matthew L. Meizlish et al. Blood Advances
- Experience with the use of siltuximab in patients with SARS-CoV-2 infection
- (2021) Fernanda Meira et al. Revista Espanola de Quimioterapia
- Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
- (2021) et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Coronavirus infections and immune responses
- (2020) Geng Li et al. JOURNAL OF MEDICAL VIROLOGY
- Reducing mortality from 2019-nCoV: host-directed therapies should be an option
- (2020) Alimuddin Zumla et al. LANCET
- IKKβ overexpression together with a lack of tumour suppressor genes causes ameloblastic odontomas in mice
- (2020) Angustias Page et al. International Journal of Oral Science
- Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients
- (2020) Yonggang Zhou et al. National Science Review
- Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
- (2020) Bingwen Liu et al. JOURNAL OF AUTOIMMUNITY
- Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial
- (2020) Bastiaan Maes et al. Trials
- An inflammatory cytokine signature predicts COVID-19 severity and survival
- (2020) Diane Marie Del Valle et al. NATURE MEDICINE
- Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19
- (2020) Enrico Brunetta et al. NATURE IMMUNOLOGY
- Pentraxin 3: Potential prognostic role in SARS-CoV-2 patients admitted to the emergency department
- (2020) Annalisa Schirinzi et al. JOURNAL OF INFECTION
- Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy
- (2019) Lara L. Riegler et al. Therapeutics and Clinical Risk Management
- Targeting Interleukin-6 Signaling in Clinic
- (2019) Sujin Kang et al. IMMUNITY
- Diagnosis and Management of Castleman Disease
- (2019) Jeremy S. Abramson Journal of the National Comprehensive Cancer Network
- Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis
- (2018) Yvette N. Lamb et al. DRUGS
- Cytokine release syndrome
- (2018) Alexander Shimabukuro-Vornhagen et al. Journal for ImmunoTherapy of Cancer
- Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What’s the Difference?
- (2018) Ali Berkant Avci et al. BIODRUGS
- Tocilizumab (Actemra)
- (2017) Martin Sheppard et al. Human Vaccines & Immunotherapeutics
- Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells
- (2016) Sylvia Heink et al. NATURE IMMUNOLOGY
- Dose selection of siltuximab for multicentric Castleman’s disease
- (2015) Christina L. Mayer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Interleukin-6: Biology, signaling and strategies of blockade
- (2015) Fred Schaper et al. CYTOKINE & GROWTH FACTOR REVIEWS
- IL-6 as a keystone cytokine in health and disease
- (2015) Christopher A Hunter et al. NATURE IMMUNOLOGY
- A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease
- (2015) Frits van Rhee et al. Oncotarget
- Exploiting interleukin 6 in multicentric Castleman's disease
- (2014) Mark Bower et al. LANCET ONCOLOGY
- Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
- (2014) Frits van Rhee et al. LANCET ONCOLOGY
- A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease
- (2013) R. Kurzrock et al. CLINICAL CANCER RESEARCH
- IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6
- (2012) Stefan Rose-John International Journal of Biological Sciences
- Maximum-Tolerated Dose, Optimum Biologic Dose, or Optimum Clinical Value: Dosing Determination of Cancer Therapies
- (2012) John L. Marshall JOURNAL OF CLINICAL ONCOLOGY
- The interleukin 6 pathway and atherosclerosis
- (2012) Jürgen Scheller et al. LANCET
- IL-6/IL-6 receptor system and its role in physiological and pathological conditions
- (2011) Masahiko Mihara et al. CLINICAL SCIENCE
- Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
- (2011) Simon A. Jones et al. JOURNAL OF CLINICAL INVESTIGATION
- Pharmacokinetic and Pharmacodynamic Modeling of an Anti-Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma
- (2010) T. Puchalski et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search